@article{3201598,
    title = "Antiplatelet and Antithrombotic Therapy in Type I Diabetes Mellitus: Update on Current Data.",
    author = "Maragkoudakis, Spyridon and Katsi, Vasiliki and Melidonis, Andreas and Soulaidopoulos, Stergios and Kolovou, Genovefa D. and Papazafeiropoulou, Athanasia K. and Trikkalinou, Aikaterini and Toutouzas, Konstantinos and Tsioufis, Constantinos",
    journal = "Current Diabetes Reviews",
    year = "2022",
    issn = "1573-3998",
    doi = "10.2174/1573399818666220103091236",
    keywords = "cardiovascular disease, venous thromboembolism, antiplatelet therapy, antithrombotic therapy, LDL, Type1 diabetes mellitus",
    abstract = "Diabetes mellitus type 1 (T1DM) is an autoimmune disease characterized by a markedly elevated cardiovascular (CV) risk due to premature atherosclerosis. Previous studies  have shown that intense glycemic control reduces the incidence of CV disease.  Antiplatelet therapy is considered to be a very important therapy for secondary  prevention of recurrent atherothrombotic events in patients with DM, while it may be  considered for primary prevention in individuals with T1DM with additional CV risk  factors.The aim of the present review is to summarize existing literature data  regarding the thrombotic risk in T1DM patients and discuss current treatment  strategies."
}